Five Things to Know About Esketamine
In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and Drug Administration (FDA) to treat patients with treatment-resistant depression (TRD). James Murrough, MD, PhD, Director of Mount Sinai’s Depression and Anxiety Center for Discovery and Treatment, was deeply involved in the research that led to esketamine’s FDA approval. In November 2019, he launched a TRD Program at the Icahn School of Medicine at Mount Sinai, featuring esketamine as a treatment option. Below, Dr. Murrough breaks down the top five things to know about esketamine based on his experience over the past decade.
Learn More
4 Things We Now Know About Treatment-Resistant Depression
For many people coping with major depressive disorder—which includes different types of depression that persist for at least two weeks—antidepressants can play an invaluable role in helping relieve symptoms, enabling them to resume the life they once enjoyed. But for those who experience a form known as treatment-resistant depression (TRD), standard medications tend to provide little to no relief.
Learn More
What Causes Depression?
Over the course of the past 100 years, our understanding of depression has greatly expanded, as has the number of therapeutic options available to deal with it. One thing researchers have learned in the past century is that, in the vast majority of cases, there is no one single cause for depression. Instead, an array of risk factors typically play into the development of a person’s depressive mood. And those risk factors are often different from person to person. Below we’re going to take a close look at what causes depression and what can be done about it. (more…)
Learn More